对一名慢性神经内脏酸性鞘磷脂酶缺乏症患儿由奥利司他α诱发的过敏性休克进行脱敏治疗

IF 1.8 4区 医学 Q3 GENETICS & HEREDITY
Laura Fiori , Veronica Maria Tagi , Chiara Montanari , Mirko Gambino , Veronica Carlevatti , Carmela Zizzo , Enza D'Auria , Dario Dilillo , Elvira Verduci , Gianvincenzo Zuccotti
{"title":"对一名慢性神经内脏酸性鞘磷脂酶缺乏症患儿由奥利司他α诱发的过敏性休克进行脱敏治疗","authors":"Laura Fiori ,&nbsp;Veronica Maria Tagi ,&nbsp;Chiara Montanari ,&nbsp;Mirko Gambino ,&nbsp;Veronica Carlevatti ,&nbsp;Carmela Zizzo ,&nbsp;Enza D'Auria ,&nbsp;Dario Dilillo ,&nbsp;Elvira Verduci ,&nbsp;Gianvincenzo Zuccotti","doi":"10.1016/j.ymgmr.2024.101120","DOIUrl":null,"url":null,"abstract":"<div><p>Olipudase alfa is indicated for the non-central nervous system manifestations of Acid sphingomyelinase deficiency (ASMD). Anaphylaxis is a very rare and life-threatening adverse reaction described for this drug. Here, we report the case of a 2-year-old boy affected by chronic neurovisceral ASMD who experienced signs of hypersensitivity reactions to olipudase alfa since the administered dose of 1 mg/kg during dose escalation and a proper anaphylactic reaction during the second administration of the target therapeutic dose of 3 mg/kg. The treatment was stopped for 15 weeks and then a 7-step desensitization protocol with the infused dose of 0.03 mg/kg was applied. Subsequent gradual dose escalation was resumed, successfully reaching the dose of 0.3 mg/kg. Moreover, biochemical, and radiological disease indexes, which were increased during treatment discontinuation, have gradually improved since the restart of treatment. However, at the second administration of the dose of 0.6 mg/kg, the patient experienced another adverse drug reaction with facial urticarial rash and bronchospasm, requiring the administration of adrenaline, methylprednisolone, and inhaled salbutamol. This case report highlights the need to customize the olipudase alfa desensitization protocol according to individual tolerance and raises the issue of achieving the established therapeutic target in the most sensitive children.</p></div><div><h3>Synopsis</h3><p>We report a case of anaphylaxis to olipudase alfa in a child affected by chronic neurovisceral Acid sphingomyelinase deficiency (ASMD) and describe a 7-step desensitization procedure. This procedure, with the total administered dose of 0.03 mg/kg, followed by gradual dose escalation, allowed to reach the dose of 0.3 mg/kg without adverse reactions; however, at the second administration of the dose of 0.6 mg/kg our patient presented another adverse reaction suggesting the need of a different desensitization strategy.</p></div>","PeriodicalId":18814,"journal":{"name":"Molecular Genetics and Metabolism Reports","volume":"40 ","pages":"Article 101120"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214426924000739/pdfft?md5=82b10ffed1460849e1b384c042dff86e&pid=1-s2.0-S2214426924000739-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Desensitization of olipudase alfa-induced anaphylaxis in a child with chronic neurovisceral acid sphingomyelinase deficiency\",\"authors\":\"Laura Fiori ,&nbsp;Veronica Maria Tagi ,&nbsp;Chiara Montanari ,&nbsp;Mirko Gambino ,&nbsp;Veronica Carlevatti ,&nbsp;Carmela Zizzo ,&nbsp;Enza D'Auria ,&nbsp;Dario Dilillo ,&nbsp;Elvira Verduci ,&nbsp;Gianvincenzo Zuccotti\",\"doi\":\"10.1016/j.ymgmr.2024.101120\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Olipudase alfa is indicated for the non-central nervous system manifestations of Acid sphingomyelinase deficiency (ASMD). Anaphylaxis is a very rare and life-threatening adverse reaction described for this drug. Here, we report the case of a 2-year-old boy affected by chronic neurovisceral ASMD who experienced signs of hypersensitivity reactions to olipudase alfa since the administered dose of 1 mg/kg during dose escalation and a proper anaphylactic reaction during the second administration of the target therapeutic dose of 3 mg/kg. The treatment was stopped for 15 weeks and then a 7-step desensitization protocol with the infused dose of 0.03 mg/kg was applied. Subsequent gradual dose escalation was resumed, successfully reaching the dose of 0.3 mg/kg. Moreover, biochemical, and radiological disease indexes, which were increased during treatment discontinuation, have gradually improved since the restart of treatment. However, at the second administration of the dose of 0.6 mg/kg, the patient experienced another adverse drug reaction with facial urticarial rash and bronchospasm, requiring the administration of adrenaline, methylprednisolone, and inhaled salbutamol. This case report highlights the need to customize the olipudase alfa desensitization protocol according to individual tolerance and raises the issue of achieving the established therapeutic target in the most sensitive children.</p></div><div><h3>Synopsis</h3><p>We report a case of anaphylaxis to olipudase alfa in a child affected by chronic neurovisceral Acid sphingomyelinase deficiency (ASMD) and describe a 7-step desensitization procedure. This procedure, with the total administered dose of 0.03 mg/kg, followed by gradual dose escalation, allowed to reach the dose of 0.3 mg/kg without adverse reactions; however, at the second administration of the dose of 0.6 mg/kg our patient presented another adverse reaction suggesting the need of a different desensitization strategy.</p></div>\",\"PeriodicalId\":18814,\"journal\":{\"name\":\"Molecular Genetics and Metabolism Reports\",\"volume\":\"40 \",\"pages\":\"Article 101120\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2214426924000739/pdfft?md5=82b10ffed1460849e1b384c042dff86e&pid=1-s2.0-S2214426924000739-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Genetics and Metabolism Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2214426924000739\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Genetics and Metabolism Reports","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214426924000739","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

摘要

奥利司他α适用于治疗酸性鞘磷脂酶缺乏症(ASMD)的非中枢神经系统表现。过敏性休克是一种非常罕见且危及生命的不良反应。在此,我们报告了一例患有慢性神经内脏性 ASMD 的 2 岁男孩的病例。在剂量升级过程中,他从给药剂量 1 毫克/千克开始就出现了对奥利司他α的超敏反应症状,并在第二次给药目标治疗剂量 3 毫克/千克时出现了适当的过敏反应。治疗停止了 15 周,然后采用了 7 步脱敏方案,输注剂量为 0.03 毫克/千克。随后又开始逐步增加剂量,并成功达到 0.3 毫克/千克的剂量。此外,停药期间升高的生化和放射疾病指标在重新开始治疗后也逐渐得到改善。然而,在第二次服用 0.6 mg/kg 剂量时,患者再次出现药物不良反应,面部出现荨麻疹和支气管痉挛,需要使用肾上腺素、甲基强的松龙和吸入沙丁胺醇。本病例报告强调了根据个体耐受性定制奥利司他α脱敏方案的必要性,并提出了在最敏感的儿童中实现既定治疗目标的问题。 简介我们报告了一例慢性神经内脏酸性鞘磷脂酶缺乏症(ASMD)患儿对奥利司他α过敏性休克的病例,并描述了一个 7 步脱敏程序。该程序的总给药剂量为 0.03 毫克/千克,随后剂量逐渐增加,使剂量达到 0.3 毫克/千克时未出现不良反应;然而,在第二次给药剂量为 0.6 毫克/千克时,患者又出现了不良反应,这表明需要采取不同的脱敏策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Desensitization of olipudase alfa-induced anaphylaxis in a child with chronic neurovisceral acid sphingomyelinase deficiency

Olipudase alfa is indicated for the non-central nervous system manifestations of Acid sphingomyelinase deficiency (ASMD). Anaphylaxis is a very rare and life-threatening adverse reaction described for this drug. Here, we report the case of a 2-year-old boy affected by chronic neurovisceral ASMD who experienced signs of hypersensitivity reactions to olipudase alfa since the administered dose of 1 mg/kg during dose escalation and a proper anaphylactic reaction during the second administration of the target therapeutic dose of 3 mg/kg. The treatment was stopped for 15 weeks and then a 7-step desensitization protocol with the infused dose of 0.03 mg/kg was applied. Subsequent gradual dose escalation was resumed, successfully reaching the dose of 0.3 mg/kg. Moreover, biochemical, and radiological disease indexes, which were increased during treatment discontinuation, have gradually improved since the restart of treatment. However, at the second administration of the dose of 0.6 mg/kg, the patient experienced another adverse drug reaction with facial urticarial rash and bronchospasm, requiring the administration of adrenaline, methylprednisolone, and inhaled salbutamol. This case report highlights the need to customize the olipudase alfa desensitization protocol according to individual tolerance and raises the issue of achieving the established therapeutic target in the most sensitive children.

Synopsis

We report a case of anaphylaxis to olipudase alfa in a child affected by chronic neurovisceral Acid sphingomyelinase deficiency (ASMD) and describe a 7-step desensitization procedure. This procedure, with the total administered dose of 0.03 mg/kg, followed by gradual dose escalation, allowed to reach the dose of 0.3 mg/kg without adverse reactions; however, at the second administration of the dose of 0.6 mg/kg our patient presented another adverse reaction suggesting the need of a different desensitization strategy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molecular Genetics and Metabolism Reports
Molecular Genetics and Metabolism Reports Biochemistry, Genetics and Molecular Biology-Endocrinology
CiteScore
4.00
自引率
5.30%
发文量
105
审稿时长
33 days
期刊介绍: Molecular Genetics and Metabolism Reports is an open access journal that publishes molecular and metabolic reports describing investigations that use the tools of biochemistry and molecular biology for studies of normal and diseased states. In addition to original research articles, sequence reports, brief communication reports and letters to the editor are considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信